Authors
Isabelle Buck, Franck Morceau, Christina Grigorakaki, Mario Dicato, Marc Diederich
Publication date
2009/5/15
Journal
Biochemical pharmacology
Volume
77
Issue
10
Pages
1572-1579
Publisher
Elsevier
Description
Erythropoiesis is considered as a multistep and tightly regulated process under the control of a series of cytokines including erythropoietin (Epo). Epo activates specific signaling pathways and leads to activation of key transcription factors such as GATA-1, in order to ensure erythroid differentiation. Deregulation leads to a decreased number of red blood cells, a hemoglobin deficiency, thus a limited oxygen-carrying capacity in the blood. Anemia represents a frequent complication in various diseases such as cancer or inflammatory diseases. It reduces both quality of life and prognosis in patients. Tumor necrosis factor alpha (TNFα) was described to be involved in the pathogenesis of inflammation and cancer related anemia. Blood transfusions and erythroid stimulating agents (ESAs) including human recombinant Epo (rhuEpo) are currently used as efficient treatments. Moreover, the recently described conflicting …
Total citations
2008200920102011201220132014201520162017201820192020202120222023202419119666336467464
Scholar articles
I Buck, F Morceau, C Grigorakaki, M Dicato… - Biochemical pharmacology, 2009